| 2. |
- Piersma, T, et al.
(författare)
-
High daily energy expenditure of incubating shorebirds on High Arctic tundra: a circumpolar study
- 2003
-
Ingår i: Functional Ecology. - : Wiley. - 1365-2435 .- 0269-8463. ; 17:3, s. 356-362
-
Tidskriftsartikel (refereegranskat)abstract
- 1. Given the allometric scaling of thermoregulatory capacity in birds, and the cold and exposed Arctic environment, it was predicted that Arctic-breeding shorebirds should incur high costs during incubation. Using doubly labelled water (DLW), daily energy expenditure (DEE) during incubation was measured in eight shorebird species weighing between 29 and 142 g at various sites in the Eurasian and Canadian High Arctic. The results are compared with a compilation of similar data for birds at lower latitudes. 2. There was a significant positive correlation between species average DEE and body mass (DEE (kJ day(-1) )=28.12 BM (g)(0.524) , r(2)=0.90). The slopes of the allometric regression lines for DEE on body mass of tundra-breeding birds and lower latitude species (a sample mostly of passerines but including several shorebirds) are similar (0.548 vs 0.545). DEE is about 50% higher in birds on the tundra than in temperate breeding areas. 3. Data for radiomarked Red Knots for which the time budgets during DLW measurements were known, indicated that foraging away from the nest on open tundra is almost twice as costly as incubating a four-egg clutch. 4. During the incubation phase in the High Arctic, tundra-breeding shorebirds appear to incur among the highest DEE levels of any time of the year. The rates of energy expenditure measured here are among the highest reported in the literature so far, reaching inferred ceilings of sustainable energy turnover rates.
|
|
| 3. |
- Rahaghi, FF, et al.
(författare)
-
Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis
- 2020
-
Ingår i: European respiratory review : an official journal of the European Respiratory Society. - : European Respiratory Society (ERS). - 1600-0617. ; 29:155
-
Tidskriftsartikel (refereegranskat)abstract
- Pulmonary sarcoidosis presents substantial management challenges, with limited evidence on effective therapies and phenotypes. In the absence of definitive evidence, expert consensus can supply clinically useful guidance in medicine. An international panel of 26 experts participated in a Delphi process to identify consensus on pharmacological management in sarcoidosis with the development of preliminary recommendations.The modified Delphi process used three rounds. The first round focused on qualitative data collection with open-ended questions to ensure comprehensive inclusion of expert concepts. Rounds 2 and 3 applied quantitative assessments using an 11-point Likert scale to identify consensus.Key consensus points included glucocorticoids as initial therapy for most patients, with non-biologics (immunomodulators), usually methotrexate, considered in severe or extrapulmonary disease requiring prolonged treatment, or as a steroid-sparing intervention in cases with high risk of steroid toxicity. Biologic therapies might be considered as additive therapy if non-biologics are insufficiently effective or are not tolerated with initial biologic therapy, usually with a tumour necrosis factor-α inhibitor, typically infliximab.The Delphi methodology provided a platform to gain potentially valuable insight and interim guidance while awaiting evidenced-based contributions.
|
|
